CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that it has entered into a definitive Equity and Assets Transfer Agreement with Kaixin Pharmaceuticals Inc., and two direct wholly-owned subsidiaries of the Company in China (the “Target Companies”), pursuant to which the Company shall sell and transfer, and Kaixin Pharmaceuticals shall purchase and acquire, 100% equity interests in both Target Companies, and all licensing rights, distribution rights, supply arrangements and related rights related to BI-1206 (in China), CID-103(in Asia excluding Japan) and Thiotepa (in China excluding Hong Kong, Macau and Taiwan) for an aggregate purchase price of $20.0 million.
Read the full article: CASI Pharmaceuticals Enters into Definitive Agreement for the Divestiture of Assets in China //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/casi-pharmaceuticals-enters-into-definitive-agreement-for-the-divesti-1026311